Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Budigalimab by AbbVie for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
Budigalimab is under clinical development by AbbVie and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According to...
Budigalimab by AbbVie for Human Immunodeficiency Virus (HIV) Infections (AIDS): Likelihood of Approval
Budigalimab is under clinical development by AbbVie and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According...
Budigalimab by AbbVie for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Budigalimab is under clinical development by AbbVie and currently in Phase III for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData,...
Budigalimab by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approval
Budigalimab is under clinical development by AbbVie and currently in Phase III for Non-Small Cell Lung Cancer. According to GlobalData,...
Budigalimab by AbbVie for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval
Budigalimab is under clinical development by AbbVie and currently in Phase I for Transitional Cell Cancer (Urothelial Cell Cancer). According...
Budigalimab by AbbVie for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Budigalimab is under clinical development by AbbVie and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC)....
Budigalimab by AbbVie for Solid Tumor: Likelihood of Approval
Budigalimab is under clinical development by AbbVie and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...